Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(13%)
Results Posted
120%(6 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_4
1
13%
Ph phase_3
5
63%
Ph phase_2
2
25%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
5(62.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Recruiting1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (25.0%)
Phase 35 (62.5%)
Phase 41 (12.5%)

Trials by Status

completed563%
recruiting113%
terminated113%
not_yet_recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
not_yet_recruitingphase_3

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264
terminatedphase_3

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

NCT06524739
recruitingphase_2

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

NCT06976476
completedphase_2

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

NCT04137224
completedphase_4

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07648264Phase 3

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Not Yet Recruiting
NCT06524739Phase 3

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Terminated
NCT06976476Phase 2

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Recruiting
NCT04137224Phase 2

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Completed
NCT03033745Phase 4

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Completed
NCT02027701Phase 3

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completed
NCT00719680Phase 3

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Completed
NCT00751621Phase 3

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8